Position of the Transparency Council – Hemlibra (emicizumab)

At its meeting on 15 July 2024, the Transparency Council adopted position No. 68/2024 on the evaluation of the drug Hemlibra (emicizumab) under the drug program “Prevention of bleeding in adults with severe hemophilia A uncomplicated by an inhibitor (ICD-10: D66)”

Publication of the position >>